GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB)

GSA Capital Partners LLP bought a new stake in shares of BioAtla, Inc. (NASDAQ:BCAB - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 353,769 shares of the company's stock, valued at approximately $623,000. GSA Capital Partners LLP owned 0.73% of BioAtla as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. AQR Capital Management LLC acquired a new position in BioAtla during the second quarter worth $872,000. Scion Asset Management LLC bought a new stake in BioAtla in the 2nd quarter valued at approximately $869,000. Bank of Montreal Can increased its position in shares of BioAtla by 55.1% in the second quarter. Bank of Montreal Can now owns 404,198 shares of the company's stock valued at $554,000 after acquiring an additional 143,521 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in BioAtla by 28.3% in the second quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company's stock valued at $458,000 after acquiring an additional 73,598 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioAtla during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 77.23% of the company's stock.

BioAtla Stock Down 0.7 %

BioAtla stock traded down $0.01 during trading hours on Tuesday, hitting $1.50. The stock had a trading volume of 859,534 shares, compared to its average volume of 856,488. The stock's 50-day moving average price is $1.91 and its 200-day moving average price is $1.85. BioAtla, Inc. has a 12-month low of $1.14 and a 12-month high of $4.02.

BioAtla (NASDAQ:BCAB - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.12. The company had revenue of $11.00 million during the quarter. During the same period last year, the business posted ($0.70) EPS. On average, analysts anticipate that BioAtla, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. HC Wainwright cut shares of BioAtla from a "buy" rating to a "neutral" rating in a research note on Wednesday, November 13th. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of BioAtla in a research note on Monday, September 16th.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.